Abstract HIV protease inhibitors (PI) are fundamental to combination antiretroviral therapy, which has revolutionized HIV clinical care and produced significant reductions in HIVassociated morbidity and mortality. However, PI administration is frequently associated with severe metabolic impairment, including lipodystrophy, dyslipidemia, and insulin resistance; all of which can contribute to cardiovascular and neurologic co-morbidities. Experimental and epidemiological data support a potentially important role for the adipokine adiponectin in both metabolic and neurologic physiology. This study examined if ADP355, a novel, peptide-based adiponectin receptor agonist, could neutralize the detrimental effects of PI treatment in experimental animal models. Adult male C57BL/6 mice were subjected to a clinically relevant, 4-week regimen of lopinavir/ritonavir, with daily injections of ADP355 administered only during the final 2 weeks of PI exposure. Comprehensive metabolic, neurobehavioral, and biochemical analyses revealed that ADP355 administration partially reversed PI-induced loss of subcutaneous adipose tissue, attenuated PI-induced hyperinsulinemia, hypertriglyceridemia, and hypoadiponectinemia, and prevented PIinduced cognitive impairment and brain injury. Collectively, these data reinforce the link between metabolic co-morbidities and cognitive impairment and suggest that pharmacological reactivation of adiponectin pathways could remediate key aspects of PI-induced metabolic syndrome in clinical settings. Furthermore, therapeutic targeting of adiponectin receptors could show utility in reducing the prevalence and/or severity of HIV-associated neurocognitive disorders.
Introduction
In the US and other developed nations, survival rates associated with HIV infection have improved dramatically since the introduction of combination antiretroviral therapies (ART), which restrict viral replication, raise CD4 cell counts, prevent opportunistic infections, and improve and extend healthrelated quality of life (Quinn 2008) . While ART has revolutionized care of HIV-positive patients, it is well known that these vital drugs have significant metabolic complications. These complications produce clinical syndromes including dyslipidemia, insulin resistance, and lipodystrophy (Anuurad et al. 2009; Barbaro 2007) , which not only affect patient health, but also limit ART compliance (Schambelan et al. 2002) . Furthermore, clinical studies reveal quite clearly that metabolic dysfunction is associated with perturbed brain function in the context of HIV/ART (Valcour et al. 2006; Bandaru et al. 2007; Foley et al. 2010; Valcour et al. 2011) . Thus, there is considerable effort undertaken to prevent or attenuate metabolic co-morbidities in clinical settings. However, current clinical strategies have not produced satisfying outcomes in HIV patients (Gutierrez and Balasubramanyam 2012) . For example, the anti-diabetic drug metformin reduces insulin resistance in HIV patients (Mulligan et al. 2007; van Wijk et al. 2011 ), but does not improve hyperlipidemia (van Wijk et al. 2011 ) and may actually accelerate lipodystrophy (Kohli et al. 2007 ). Thiazolidinediones (TZDs) have been shown to improve insulin sensitivity (Mulligan et al. 2007; van Wijk et al. 2011 ), but also increase hyperlipidemia (Mulligan et al. 2007; van Wijk et al. 2011 ) and accelerate bone loss in HIV patients (Wei and Wan 2011) . Statins are contraindicated for use in HIV because of drug interactions involving the CYP450 system (Jiménez-Nácher et al. 2011) . Human recombinant growth hormone (hrGH) has been used off-label to treat lipodystrophy in HIV patients. Indeed, tesamorelin, a synthetic analogue of human growth hormone-releasing hormone and the only FDA-drug approved to treat HIV lipodystrophy, decreases excess accumulation of abdominal fat, reduces triglyceride levels and improves glucose homeostasis (Spooner and Olin 2012) . However, studies have shown that hrGH may decrease extremity fat mass, increase insulin resistance, as well as induce arthralgia and edema (Sivakumar et al. 2011 ). Thus, new therapeutic targets and approaches to significantly and successfully mitigate different co-morbidities in HIV patients are needed.
In this context, therapies that prevent the loss of adipocytes and/or replicate adipocyte function in the face of adiposopathy could provide novel and innovative strategies to preserve physiologic function in HIV patients. Adipocytes regulate many physiologic processes via secretion of adipokines (Rocha and Libby 2008) ; and in particular, adiponectin may be key to the maintenance of overall health. In terms of physiology, adiponectin is known modulate a number of key processes, including glucose regulation, vascular tone, and fatty acid metabolism (Siasos et al. 2012) . Adiponectin also has both vasculoprotective and neuroprotective properties (Chen et al. 2009; Jung et al. 2006; Ouedraogo et al. 2007) , and low levels of plasma adiponectin predict both cognitive impairment (Kamogawa et al. 2010 ) and decreased hippocampal volume (Masaki et al. 2012) . Finally, serum adiponectin levels are decreased in HIV patients (Kinlaw and Marsh 2004; Leszczyszyn-Pynka et al. 2005; Veloso et al. 2012) , and hypoadiponectinemia correlates with cognitive dysfunction in ART-treated mice (Gupta et al. 2012 ). These observations suggest that adiponectin replacement therapy could remediate metabolic dysfunction and maintain neurologic performance in the context of chronic ART therapy. However, adiponectinbased therapeutics are presently not available, likely due to difficulties in converting the full size adiponectin protein into a viable drug. Recently, we generated a short adiponectin peptidomimetic, ADP355. The peptide contains adiponectin active site, mimics adiponectin action in vitro acting through the adiponectin receptor 1/2, demonstrates anti-neoplastic efficacy in vivo, and features great stability in biological fluids as well as a favorable toxicity profile (Otvos et al. 2011 ). As such, ADP355 could be a potential candidate for adiponectin replacement therapy in metabolic conditions characterized by hypoadiponectinemia. As adiponectin-based therapies in lipodystrophy models have never been tested, this study was designed to determine if ADP355 could mitigate PI-induced metabolic dysfunction and preserve CNS physiology in experimental animals. To this end, C57BL/6 mice were subjected to a clinically relevant, 4-week regimen of lopinavir/ ritonavir, with daily injections of ADP355 administered during the final 2 weeks of PI exposure, followed by extensive testing for metabolic and neurologic function.
Materials and Methods

Synthesis and Purification of ADP355 Peptide
The adiponectin-based peptidomimetic ADP355 (H-DAsnIle-Pro-Nva-Leu-Tyr-DSer-Phe-Ala-DSer-NH2) was synthesized on the solid-phase by using a CEM Liberty microwaveassisted peptide synthesizer and utilizing Fmoc-chemistry, purified by RP-HPLC, and verified using MALDI-MS as previously reported (Otvos et al. 2011) . After purification, ADP355 was lyophilized twice from 2 % aqueous acetic acid solution prior to cellular efficacy studies.
Animal Treatments
The Institutional Animal Care and Use Committee at the Pennington Center approved all experimental protocols, which were compliant with NIH guidelines on the use of experimental animals. 6-8 month-old male C57Bl/6 mice were purchased from Charles River Laboratories (Wilmimgton, MA), and were housed in standard caging with 12:12 light: dark cycle and ad libitum access to food and water. Lopinavir/ritonavir (Kaletra®, Abbott Laboratories), was diluted in a vehicle of 10 % ethanol/15 % propylene glycol, and mice received daily administration of vehicle or lopinavir/ritonavir at 150/37.5 mg/kg via oral gavage. The dose was devised based on dosing guidelines for daily oral lopinavir/ritonavir in adult HIV patients (800/200 total mg or 10/2.5 mg/kg), and on body surface area (BSA) normalization factors (Reagan-Shaw et al. 2007 ), which translate 10 mg/kg in humans to approximately 125 mg/kg in mice.
After experimental mice had been treated with lopinavir/ ritonavir or vehicle for 2 weeks, randomly selected mice from each group were treated daily with vehicle (phosphate buffered saline (PBS)) or ADP355 (1 mg/kg in PBS) via intraperitoneal injection for an additional 14 days (28 total days of lopinavir/ritonavir exposure).
Body weight and composition (measured using a Bruker minispec LF90 time domain NMR analyzer, Bruker Optics, Billerica MA) were measured regularly throughout lopinavir/ ritonavir exposure. Blood glucose was measured in tail blood using a glucometer (Ascensia Elite, Bayer, Mishawaka, IN). After cognitive testing (see Section "Fear Conditioning Memory Task"), all mice were humanely euthanatized after a brief (6 h) fast, and blood, adipose tissue, and brain were collected. Data were compiled from 3 separate cohorts of mice, with a total of 9-20 animals in each group.
Fear Conditioning Memory Task
Each mouse was individually evaluated for fear conditioning using an automated, video-based fear conditioning system (Med-Associates, St. Albans, VT). The fear conditioning assay is a type of associative learning task in which subjects are presented with a neutral stimulus (tone) that is paired with an aversive unconditioned stimulus (foot shock), subjects display fear behavior (freezing) in response to the tone. This task does not require the animals to swim, and is not confounded by changes in nociception, food-seeking behavior, hunger, or fatigue. The apparatus consists of a "startle chamber" used on days 1 and 2, which is an 8×15×15-cm acrylic and wire mesh cage located within a custom designed 90×70×70 ventilated sound-attenuating chamber. The floor of each chamber is made of 2.0-mm diameter stainless steel bars spaced 6 mm apart, through which shock is administered, and the unique context is reinforced with an anise-based scent applied to each cage before testing. Animal movement within the apparatus results in displacement of an accelerometer (model U321AO2; PCB Piezotronics, Depew, NY, USA) with the resulting voltage being proportional to the velocity of displacement. For day 3, an entirely separate chamber located in a different room is used to remove all contextual cues. These "trace" chambers contain a flat floor instead of the grid, a"teepee"-shaped insert to modify the chamber dimensions, and an acetic acid odor used to reinforce the novel environment.
Acquisition of fear conditioning on day 1 consisted of 5 min of acclimation to the startle chamber, followed by five consecutive 30 s auditory stimuli (85 dB, 4 KHz) that coterminated with a mild footshock (0.5 mA×1 s), with 30 s recovery periods between tones. On day 2, the mice were returned to the same chambers, but no stimuli were applied to evaluate freezing responses to context. On day 3, the mice were placed in the novel "trace" chambers, and after habituation of the mice within the chambers for 5 min, a continuous tone (85 dB, 4 KHz) was applied for 5 min. The percent of freezing was recorded as a measure of trace memory of the conditioned response to the tone.
Clinical Chemistry
Whole blood was collected by cardiac puncture of terminally anesthetized mice, and was allowed to clot at 4ºC overnight and then centrifuged at 3000xg for 30 min. Serum was collected and either analyzed immediately or aliquoted and stored at −80ºC. Levels of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and nonesterified fatty acids (NEFA) in sera were measured colorimetrically using commercially available kits (Wako Chemicals, Richmond, VA). Adiponectin, leptin, and insulin levels in serum were evaluated by ELISA in accordance with the manufacturer's assay protocol (R&D Systems, Minneapolis, MN for adiponectin and leptin; and Crystal Chem Inc., Downers Grove IL for insulin). To measure total pools of adiponectin, serum samples were first denatured (boiled in SDS buffer for 5 min) to break down large complexes.
Evaluation of Brain Injury Markers by Western Blot
Tissue samples were homogenized and processed for Western blot with chemiluminescence as described in previous reports (Pistell et al. 2010b ). Blots were processed using the following primary antisera: anti-claudin-5 (1:400, Abcam Inc., Cambridge, MA), anti-ZO-1 (1:100, Abcam Inc.), anti-occludin (1:8000, Abcam Inc.), anti-MMP2 (1:1000, Abcam Inc.), anti-MMP-9 (1:1000, Abcam Inc.), anti-synapsin 1 (1:10000, Thermo Fisher Scientific, Pittsburg, PA), antiphospho(S553)-synapsin 1 (1:10000, Abcam Inc.), antisynapse associated protein 97 (1:2500, Abcam Inc.), anti-GFAP (1:5000, Abcam Inc.); anti-Iba-1 (1:500, Wako Chemicals USA Inc., Richmond, VA), and anti-tubulin (1:1000, Wako Chemicals USA Inc.). To ensure accurate quantification across multiple blots, samples from all treatment groups (vehicle, liponavir/ritonavir/PBS, and liponavir/ ritonavir/ADP355) were included in each individual blot. Data were first calculated as a ratio of expression over tubulin expression, which was included as an internal loading control, and then expression in liponavir/ritonavir/PBS and liponavir/ ritonavir/ADP355 was calculated and presented as percent expression in control (vehicle) mice.
Statistical Analyses
All data were analyzed using Prism software (GraphPad Software, Inc., La Jolla, CA), and are displayed as mean ± standard error of measurement. Body weight and composition was analyzed with 2-way repeated measures ANOVA to determine main effects of drug treatment and duration, followed by planned Bonferroni post-hoc comparisons to determine differences between in groups (vehicle, vehicle/ADP355, liponavir/ritonavir/PBS, and liponavir/ritonavir/ADP355). All other data were analyzed by 1-way ANOVA followed by Tukey's Multiple Comparison post-hoc tests to determine specific differences between groups. Statistical significance for all analyses was accepted at p<0.05, and *, **, and *** represent p<0.05, p<0.01, and p<0.001, respectively.
Results
Effects ADP355 on Body Weight and Composition in Lopinavir/Ritonavir-Treated Mice
Previous studies from our laboratory and others have clearly shown that exposure of mice to lopinavir/ritonavir (Kaletra®, Abbott Laboratories, Abbott Park, IL), a protease inhibitor cocktail commonly used in clinical settings to manage HIV produces a severe metabolic derangement also associated with cognitive impairment (Pistell et al. 2010a; Gupta et al. 2012) . To determine therapeutic potential ADP355 against PIinduced metabolic and neurologic dysfunction, ADP355 was applied daily to selected 6-8 month old, male C57BL/6 mice for the final 2 weeks of a 4-week regimen of lopinavir/ ritonavir or vehicle as described in Methods. Body weight and body composition measurements taken throughout treatment demonstrated that neither lopinavir/ritonavir nor ADP355 caused significant alterations in body weight (Fig. 1a) . However, lopinavir/ritonavir-treated mice did lose significant amounts of total body fat relative to vehicle-treated mice after 2, 3, and 4 weeks of exposure (Fig. 1b) . PIdependent loss of adipose tissue was partially reversed by administration of ADP355 (Fig. 1b) . There were no effects, however, of ADP355 on total body fat in vehicle-treated mice (Fig. 1b) .
To further examine the beneficial effects of ADP355 on lopinavir/ritonavir-induced lipoatrophy, individual subcutaneous (inguinal) and visceral (epididymal and retroperitoneal) adipose depots were collected and were weighed. Lopinavir/ ritonavir treatment resulted in significant reductions in the weight of the subcutaneous inguinal adipose depot (Fig. 2a) . However, subcutaneous fat depots were significantly larger in lopinavir/ritonavir-treated mice given ADP355 compared to mice given PBS (Fig. 2a) although inguinal fat pads in ADP355-treated mice remained smaller than those isolated from vehicle-treated mice. Conversely, while lopinavir/ ritonavir significantly reduced the weight of the epididymal (Fig. 2b ) and retroperitoneal (Supplemental Fig. 1 ) adipose depots, ADP355 did not prevent lopinavir/ritonavir-induced loss of visceral fat ( Fig. 2b and Supplemental Fig. 1 ), suggesting a selective beneficial effect of ADP355 on subcutaneous fat. Finally, ADP355 did not affect the weight of any adipose depots in vehicle treated mice (Fig. 2) .
Effects ADP355 on Serum Markers of Metabolic Syndrome
To determine the effects of ADP355 on PI-induced metabolic syndrome, metabolic data relating specifically to insulin resistance, hyperlipidemia, and adipokine secretion were collected at the end of the 28-day PI exposure period. To document insulin sensitivity, studies focused on measurement of fasting levels of blood glucose and serum insulin, as described in Methods. Lopinavir/ritonavir treatment resulted in moderate but significant increases in fasting glucose levels and dramatic elevations in serum insulin (Fig. 3a and b) . While administration of ADP355 did not affect PI-induced hyperglycemia, the peptide completely inhibited PI-dependent hyperinsulinemia (Fig. 3b) . ADP355 did not affect glucose or insulin levels in vehicle treated mice (Fig. 3) . Fig. 1 ADP355 preserves total body fat in PI-treated mice. Male C57BL/ 6 mice were given daily oral gavage administration of 10 % ethanol/15 % propylene glycol (vehicle; closed circles) or 150 mg lopinavir/37.5 mg ritonavir/kg (PI; closed circles) for 28 days. Additionally, after 14 days of PI exposure, randomly selected vehicle (vehicle/ADP; closed squares) and PI-treated mice (PI/ADP; open squares) mice were also treated daily with ADP355 (1 mg/kg) or PBS via intraperitoneal injection for the final 14 days of PI exposure. All mice were evaluated regularly for (a) body weight and (b) total body fat mass expressed as percent measured at day 0. All data are mean and S.E.M. of 9-21 mice per group. Data were analyzed by 2-way ANOVA, and *** indicates significant (p<0.001) differences noted in PI and PI/ADP and treated mice as compared to vehicle-treated mice at the same timepoint. ## indicates significant (p<0.01) differences in total body fat between PI and PI/ADP355 mice Hypertriglyceridemia is a well-established side-effect of protease inhibitor treatment in both mice and humans. Thus our next studies assessed a panel of bioactive serum lipids in PI-treated and control mice. A significant, near 3-fold increase in serum triglycerides was detected in mice given lopinavir/ ritonavir (Fig. 3c) . Delayed administration of ADP355 significantly reduced lopinavir/ritonavir-induced hypertriglyceridemia (Fig. 3c) , although triglyceride levels in ADP355-treated mice remained elevated relative to vehicle-treated mice. Lopinavir/ritonavir also increased levels of total cholesterol levels, but this effect was not affected by ADP355 (Table 1) . Finally, levels of LDL cholesterol, HDL cholesterol, and circulating non-esterified fatty acids (NEFA) were not Fig. 2 ADP355 preserves subcutaneous, but not visceral fat depots in PItreated mice. Male C57BL/6 mice were given daily administration of 10 % ethanol/15 % propylene glycol (vehicle; left bars) or 150 mg lopinavir/37.5 mg ritonavir/kg (PI; right bars) for 28 days. Additionally, randomly selected vehicle (open bars) and PI-treated mice (hatched bars) mice were also treated daily with ADP355 (1 mg/kg) or PBS via intraperitoneal injection for the final 14 days of PI exposure, after which all mice were euthanatized and subcutaneous inguinal and visceral epididymal fat pads were collected and weighed. Data are means ± S.E.M. of fat pad mass in milligrams, and were generated from 9-21 mice per group. a Inguinal fat depot weight in vehicle and lopinavir/ritonavir-treated mice following administration of PBS or ADP355. *** and ** indicates significant (p<0.001 and p<0.01) decreases in weight of the inguinal fat depot in lopinavir/ritonavir/PBS and lopinavir/ritonavir/ADP355 mice as compared to vehicle-treated mice, respectively. # indicates significant (p<0.05) increase in weight of the epididymal fat depot in lopinavir/ ritonavir/ADP355 mice compared to lopinavir/ritonavir/PBS mice. b Epididymal fat depots in vehicle and lopinavir/ritonavir-treated mice following administration of PBS or ADP355. *** and ** indicates significant (p<0.001 and p<0.01, respectively) decreases in weight of the inguinal fat depot in lopinavir/ritonavir/ADP355 and lopinavir/ritonavir/PBS mice as compared to vehicle-treated mice, respectively Fig. 3 ADP355 attenuates circulating serum insulin and triglycerides, but not blood glucose, in PI-treated mice. Male C57BL/6 mice were given daily administration of 10 % ethanol/15 % propylene glycol (vehicle; left bars) or 150 mg lopinavir/37.5 mg ritonavir/kg (PI; right bars) for 28 days. Additionally, randomly selected vehicle (open bars) and PI-treated mice (hatched bars) mice were also treated daily with ADP355 (1 mg/kg) or PBS via intraperitoneal injection for the final 14 days of PI exposure, after which all mice were euthanatized and serum was collected from whole blood. Data are means ± S.E.M. and were generated from 9-21 mice per group. a Fasting blood glucose levels measured in vehicle and lopinavir/ ritonavir-treated mice after administration of PBS or ADP355. *** and ** indicates significant (p<0.001 and p<0.01, respectively) increases in fasting blood glucose in lopinavir/ritonavir-treated mice given either PBS or ADP355, respectively, as compared to vehicle-treated mice. b Fasting insulin levels measured in vehicle and lopinavir/ritonavir-treated mice after administration of PBS or ADP355. *** indicates significant (p<0.001) increase in fasting insulin in lopinavir/ritonavir-treated given PBS as compared to vehicle-treated mice, while ## depicts significant (p<0.01) decrease in fasting insulin in lopinavir/ritonavir-treated mice given ADP355 as compared to lopinavir/ritonavir-treated given PBS. c Fasting triglyceride levels measured in vehicle and lopinavir/ritonavirtreated mice after administration of PBS or ADP355. *** indicates significant (p<0.001) increase in triglycerides in both groups of mice given lopinavir/ritonavir, while # depicts significant (p<0.05) decrease in triglycerides measured in lopinavir/ritonavir-treated mice given ADP355 as compared to lopinavir/ritonavir-treated given PBS significantly affected by lopinavir/ritonavir or ADP355 (Table 1) .
The loss of adipose tissue lopinavir/ritonavir-treated mice was paralleled with significant and profound decreases in circulating levels of adiponectin and leptin (Fig. 4) . PIinduced hypoadiponectinemia was partially reversed by delayed administration of ADP355 (Fig 4a) , but ADP355 was not able to prevent lopinavir/ritonavir-induced hypoleptinemia (Fig. 4b) and did not modulate serum resistin levels (Supplemental Fig. 1 ). Finally, ADP355 did not significantly affect adipokine levels in vehicle-treated mice (Fig. 4) .
Effects of ADP355 on Cognitive Performance and Markers of Brain Injury in Lopinavir/Ritonavir-Treated Mice
We have previously shown that chronic administration of combined lopinavir/ritonavir causes significant impairments in memory performance, but does not affect motor function (Pistell et al. 2010a; Gupta et al. 2012) . To determine the effects of ADP355 on PI-induced memory impairment, the fear conditioning assay was implemented as described in Methods. Significant differences in freezing behavior were observed on the third day of the fear conditioning test, when the "tone test" that provides a measure of associative learning was deployed (Fig. 5) . Specifically, freezing behavior in response to the tone was dramatically decreased in lopinavir/ ritonavir-treated mice as compared to vehicle-treated mice (Fig. 5) . However, this PI-induced memory impairment was completely prevented by ADP355 administration (Fig. 5) .
PI-induced brain injury was quantified by evaluating the expression of specific brain proteins, as described previously (Gupta et al. 2012) . Analyses were thematically split into evaluations of cerebrovascular integrity, synaptic density, and reactive gliosis conducted in the cerebral cortex as cortical injury has been shown to be caused by PI exposure in mice (Gupta et al. 2012) , and also to perturb performance in the fear conditioning task in rodents (Han et al. 2012 ). Cerebrovascular and blood-brain barrier integrity were evaluated by measuring the expression of tight junction proteins ZO-1 and Male C57BL/6 mice were given daily administration of 10 % ethanol/15 % propylene glycol (vehicle) or 150 mg lopinavir/37.5 mg ritonavir/kg (PI) for 28 days. Additionally, randomly selected vehicle and PI-treated mice were also treated daily with ADP355 (1 mg/kg) or PBS via intraperitoneal injection for the final 14 days of PI exposure, after which all mice were euthanatized and serum lipids were measured as described in Methods
Data are means ± S.E.M. generated from 9-21 mice per group, and were analyzed by 1-way ANOVA followed by planned Tukey posttests to determine the effects of ADP355 in PI-and vehicle-treated mice a Indicates significant (p<0.05) increases in total cholesterol in mice given either lopinavir/ritonavir/PBS or lopinavir/ritonavir/ADP355 as compared to vehicle-treated mice Fig. 4 ADP355 preserves circulating serum adiponectin but not leptin in PI-treated mice. Male C57BL/6 mice were given daily administration of 10 % ethanol/15 % propylene glycol (vehicle; left bars) or 150 mg lopinavir/37.5 mg ritonavir/kg (PI; right bars) for 28 days. Additionally, randomly selected vehicle (open bars) and PI-treated mice (hatched bars) mice were also treated daily with ADP355 (1 mg/kg) or PBS via intraperitoneal injection for the final 14 days of PI exposure, after which all mice were euthanatized and serum was collected from whole blood. a Effects of lopinavir/ritonavir with or without ADP355 on serum adiponectin concentration. Data are means ± S.E.M. of adiponectin expressed as pg/μl serum, and were analyzed by 1-way ANOVA. *** indicates significant (p<0.001) decrease in adiponectin in both groups of mice given lopinavir/ritonavir, while ## depicts significant (p<0.01) increase in adiponectin levels in lopinavir/ritonavir-treated mice given ADP355 as compared to lopinavir/ritonavir-treated given PBS. b Effects of lopinavir/ritonavir with or without ADP355 on serum leptin concentration. Data are means ± S.E.M. of leptin expressed as ng/ml serum, and were analyzed by 1-way ANOVA. ** indicates significant (p>0.01) decreases in leptin in lopinavir/ritonavir-treated mice given either PBS or ADP355 as compared to vehicle-treated mice occludin, as well as the matrix metalloproteinases MMP2 and MMP9, as described in Methods. Data show that lopinavir/ ritonavir-treated mice given PBS showed significantly decreased expression of occludin and increased expression of MMP2 as compared to vehicle-treated mice (Fig. 6a) . Conversely, lopinavir/ritonavir-treated mice given ADP355 showed significant reversals in the expression of occludin and MMP2, and indeed, no markers of cerebrovascular injury in lopinavir/ritonavir/ADP355-treated were statistically different from vehicle-treated mice (Fig. 6a) . Evaluations of synaptic density were based on altered expression of the post-synaptic protein synapse associated protein 97 (SAP97) and total and phosphorylated forms of the pre-synaptic protein synapsin 1 (SYN1). Total levels of SAP97 and total SYN1 were similar in all groups (Fig. 6b) , but phosphorylated SYN1 expression was significantly reduced in liponavir/ritonavir mice relative to controls (Fig. 6b) . However, SYN1 phosphorylation was completely preserved in liponavir/ritonavir-treated mice given ADP355
To determine the effects of ADP355 on liponavir/ritonavirinduced reactive gliosis, the expression of astrocyte and microglial markers were evaluated using Western blot. PI treatment significantly increased the expression of glial fibrillary acidic protein (GFAP), an intermediate filament protein and a marker of astrocyte hypertrophy. Administration of ADP355, however, did not modulate astrocyte reactivity (Fig. 6c) . Microgliosis was evaluated by measuring expression of Iba-1, a 17-kDa calcium binding protein specifically expressed in macrophages/microglia that can be detected in denatured samples. Liponavir/ritonavir caused significant increases in Iba-1 expression relative to vehicle controls (Fig. 6c) , while lopinavir/ritonavir mice given ADP355 showed complete reversal of PI-induced microgliosis (Fig. 6c) .
Discussion
It is well-established that ART frequently causes a pathologic sequela of metabolic derangement in HIV patients that likely contributes to co-morbidities in this patient population. Data in this manuscript demonstrate the protective effects of a novel, peptide-based adiponectin receptor agonist against metabolic and neurologic dysfunction caused by the lopinavir/ritonavir cocktail in mice. ADP355 administration moderated PI-induced loss of subcutaneous adipose, attenuated PI-induced hyperinsulinemia, hypertriglyceridemia, and hypoadiponectinemia, and completely prevented PI-induced cognitive impairment and brain injury. Collectively, these data indicate that ART-induced lipodystrophy and the resulting hypoadiponectinemia may be key players driving metabolic dysfunction in HIV patients, which could sensitize patients to HIV-associated neurocognitive disturbances. This scenario is in general agreement with clinical studies showing that HIV patients with metabolic compromise have a greater risk of developing neurologic complications (Valcour et al. 2006; Bandaru et al. 2007; Valcour et al. 2011; Foley et al. 2010) . Furthermore, cognitive impairment in adult HIV patients has been shown to correlate with cardiovascular disease, hypertension, and cholesterolemia; but not with conventional risk factors for dementia, including CD4 cell counts, viral load, CNS penetration of ART, hepatitis C infection, or alcohol abuse (Wright et al. 2010) . As epidemiological studies indicate, HIV remains the most common preventable and treatable cause of neurologic impairment in patients under the age of 50 (Ances and Ellis 2007) . Additionally, recent clinical trials using neuroprotective or anti-inflammatory drugs for treatment of HIV-associated neurocognitive disorders have generally proven unsuccessful (Tan and McArthur 2012) . Thus, there is a critical need to develop novel and innovative therapies to preserve neurologic function in HIV patients. Data in this manuscript raise the exciting possibility that pharmacological activation of adiponectin receptors in HIV patients could not only mitigate key aspects of ART-induced metabolic syndrome but also decrease the incidence and/or severity of HIV-associated neurocognitive disorders.
Lipodystrophy is highly common in HIV patients and is tightly associated with other metabolic co-morbidities, including insulin resistance and hyperlipidemia (Paruthi et al. 2013) . Indeed, there is evidence that lipodystrophy, which has a Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/37.5 mg/kg body weight) for 28 days, after which mice were evaluated behaviorally for memory performance using the fear conditioning assay as described in Methods. Experiments were conducted in 12-20 animals per group over 2 separate cohorts. Data are means ± S.E.M. of composite freezing behavior, and were analyzed by 2-way ANOVA. *and *** indicate significant (p<0.05, p<0.001, respectively) decreases in freezing behavior in lopinavir/ritonavir/PBS-treated mice as compared to vehicle-treated mice, while # and ### depict significant (p<0.05, p<0.001, respectively) increases in freezing in lopinavir/ritonavir-treated mice given ADP355 as compared to lopinavir/ritonavir-treated given PBS prevalence of up to 83 % and was widely reported only after the introduction of ART, may actually precede and precipitate the development of broader metabolic complications (dyslipidemia, insulin resistance) in HIV-patients (Barbaro 2007; Arai et al. 2011 ). Thus, therapies that prevent the loss of adipocytes and/or replicate adipocyte function in the face of lipodystrophy could preserve metabolic function in HIV patients. Evidence of decreased adiponectin levels in HIVpositive patients with lipodystrophy (Kinlaw and Marsh 2004; Barbaro 2007; Chen et al. 2009 ), and the negative correlation between adiponectin and insulin resistance (Arama et al. 2013 ) support investigation of the protective effects of adiponectin in models of HIV. Data in this manuscript show that delayed treatment with ADP355 peptide was able to partially reverse adipose tissue depletion in HIV protease inhibitor-treated mice, and that this partial preservation of adipose mass was associated with preservation of insulin and triglyceride levels. Furthermore, the protective effects of ADP355 against lipoatrophy appeared preferentially directed towards subcutaneous rather than visceral fat. Such findings could have important and exciting clinical ramifications as subcutaneous fat has intrinsic beneficial metabolic properties (Gil et al. 2011) , but is particularly vulnerable to ART-induced lipoatrophy (de Waal et al. 2013) . Subcutaneous and visceral adipocytes derive from different progenitor cells that exhibit a different gene expression pattern, and thus may respond quite differently to the effects of adiponectin receptor stimulation. Indeed, gene expression of AdipoR1 has been reported to be 2-fold higher, and AdipoR2 expression as much as~10-fold higher, in subcutaneous as compared to visceral fat (Nannipieri et al. 2007 ), which could explain in part the preferential preservation of subcutaneous adipose by ADP355.
Delayed treatment with ADP355 peptide completely prevented neurologic decline in PI-treated mice, supporting existing data showing that adiponectin receptor signaling can support neurologic health (Oomura et al. 2006; Harvey 2007; Ouchi and Walsh 2007; Chen et al. 2009; Jung et al. 2006) . The protective effect of ADP355 on neurologic function is likely mediated through multiple mechanisms but could include direct actions on neurons. While the exact role of adiponectin in the brain is still subject to debate, there is substantial evidence of adiponectin receptor expression in Fig. 6 ADP355 preserves markers of cerebrovascular integrity, synaptic density, and modulates reactive gliosis in PI-treated mice. Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/ 37.5 mg/kg body weight) for 28 days, after which markers of cerebrovascular integrity, synaptic density, and reactive gliosis were evaluated in tissue homogenates prepared from the frontal cortex as described in Methods. Data depict mean ± SEM expression in lopinavir/ritonavirtreated mice presented as % vehicle (100 % line) on graph. Data were obtained from 12-20 mice/group, and were analyzed by 1-way ANOVA. a Expression of the tight junction proteins claudin-5, ZO-1, and occludin; and the matrix metalloproteinases MMP2 and MMP9. * and ** indicate significant (p<0.05 and 0.01, respectively) changes in expression in lopinavir/ritonavir/PBS-treated mice as compared to vehicle, while # and ## depict significant (p<0.05, p<0.01, respectively) changes in expression in lopinavir/ritonavir-treated mice given ADP355 as compared to lopinavir/ritonavir-treated given PBS. b Expression of the postsynaptic marker synapse associated protein 97 (SAP97), the pre-synaptic protein synapsin 1, and phosphorylated synapsin 1. *** indicates significant (p<0.001) the significant decrease in phosphorylated synapsin 1 expression in lopinavir/ritonavir/PBS-treated mice relative to vehicle mice, while # depicts the significant (p<0.05) reversal in phosphorylated synapsin 1 expression in lopinavir/ritonavir-treated mice given ADP355. c Expression of the glial markers GFAP and Iba-1. * indicates significant (p<0.05) increases in GFAP and Iba-1 expression in lopinavir/ritonavirtreated mice relative to vehicle-treated mice, while # depicts the significant (p<0.05) reversal in Iba-1 expression in lopinavir/ritonavir-treated mice given ADP355 brain cells Fry et al. 2006; 
